[ad_1]
At the beginning of the pandemic, there were a number of studies in China that showed that heart-specific markers in the blood were elevated in COVID-19 patients.
Studies found that the higher the levels of these cardiac markers in the blood, the greater the risk of severe covid-19.
A new study by researchers at Akershus University Hospital, led by Professor Torbjørn Omland, published in the world’s leading cardiac journal Circulation, now strikes a chord with early Chinese findings.
see more
No context
The group’s main finding is that cardiac markers in the blood, which are often elevated in COVID-19 patients, do not necessarily imply as bad a prognosis as was initially thought.
Therefore, the researchers found that there is no connection between cardiac blood levels of markers and respiratory treatment or death, when common risk factors were taken into account.
Therefore, it seems that there is no point in measuring these cardiac markers in anyone with COVID-19 to assess prognosis.
Chief physician: tendon injuries after crown
– The great strength of our study is that it is prospective, it is planned in advance and we have taken samples from all patients. So we have everyone, not just a selected group. It is clear that if you in a sample have an excessive frequency of people with heart problems from before, then the result will be different, says Ahus’ doctor and researcher, Peder L. Myhre, to Dagbladet.
Weakness
A weakness of the early Chinese studies is that they were conducted retrospectively based on patient records, with a high probability of population bias, as it is often patients with known heart disease who are screened for markers heart disease in the blood.
– At the beginning of the pandemic, there was a great need for information about covid-19. Now there seems to be a hunger for studies that have been done in a more robust way, and therefore our study is printed in Circulation, the best gossip journal in the world, Myhre says.
The researcher says the Norwegian study is important because they still want to find real markers that show who is most exposed to severe COVID-19.
Myhre warns that more new insights will be gained from Ahus’s Norwegian research group soon.
– Already in February we began to plan our study, with the aim of finding the reasons why some get so sick from covid-19, while others do not. It’s absolutely important to find good answers to this, so that you can give intensified treatment to those with a poor prognosis and lower your shoulders a little in those with a good prognosis, Myhre says.
“Our findings contrast with retrospective reports from China. Discrepancies may be related to differences in study design. If risk initially affects the indication for biomarker measurement, selection bias is introduced,” the study states.
